Depending on the mutational consequence, some CHI patients are responsive to treatment by the potassium channel opener diazoxide, and KATP-openers may indeed prove beneficial in some AIMS patients. The gene discussed is KCNA3; the disease is congenital isolated hyperinsulinism.